- Home
- FAAS vs BRNS Comparison
FAAS vs BRNS Comparison
Compare FAAS & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- BRNS
- Stock Information
- Founded
- FAAS 2021
- BRNS 2016
- Country
- FAAS Indonesia
- BRNS United Kingdom
- Employees
- FAAS N/A
- BRNS N/A
- Industry
- FAAS
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- FAAS
- BRNS Health Care
- Exchange
- FAAS NYSE
- BRNS Nasdaq
- Market Cap
- FAAS 48.2M
- BRNS 40.0M
- IPO Year
- FAAS N/A
- BRNS 2021
- Fundamental
- Price
- FAAS $0.59
- BRNS $0.90
- Analyst Decision
- FAAS
- BRNS Strong Buy
- Analyst Count
- FAAS 0
- BRNS 1
- Target Price
- FAAS N/A
- BRNS $3.00
- AVG Volume (30 Days)
- FAAS 8.7M
- BRNS 12.7K
- Earning Date
- FAAS 01-01-0001
- BRNS 08-07-2025
- Dividend Yield
- FAAS N/A
- BRNS N/A
- EPS Growth
- FAAS N/A
- BRNS N/A
- EPS
- FAAS N/A
- BRNS N/A
- Revenue
- FAAS $57,730,593.00
- BRNS $14,969,000.00
- Revenue This Year
- FAAS N/A
- BRNS N/A
- Revenue Next Year
- FAAS N/A
- BRNS N/A
- P/E Ratio
- FAAS N/A
- BRNS N/A
- Revenue Growth
- FAAS 38.16
- BRNS 4381.74
- 52 Week Low
- FAAS $0.16
- BRNS $0.64
- 52 Week High
- FAAS $7.25
- BRNS $1.58
- Technical
- Relative Strength Index (RSI)
- FAAS 49.36
- BRNS 50.69
- Support Level
- FAAS $0.50
- BRNS $0.83
- Resistance Level
- FAAS $0.65
- BRNS $0.95
- Average True Range (ATR)
- FAAS 0.11
- BRNS 0.05
- MACD
- FAAS -0.03
- BRNS -0.01
- Stochastic Oscillator
- FAAS 24.10
- BRNS 45.35
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.